.png){kind=small}
.png){kind=small}
BackTable / Tumor Board / Contributor
Dr. Mark Tyson
Urologic Oncologist
Dr. Mark Tyson is a urologic oncologist and professor of urology with Mayo Clinic in Scottsdale, Arizona.
Listen to Dr. Mark Tyson on the BackTable Podcast
The BackTable Podcast is a knowledge resource by physicians for physicians. Learn from the experiences and expertise of Dr. Mark Tyson and get practical advice on how to build your practice by listening to the BackTable Podcast.
Stay Up To Date
Follow:
Subscribe:
Sign Up:
About Dr. Mark Tyson
Dr. Mark Tyson is a urologic oncologist, with subspecialty interest in bladder cancer. His clinical focus includes: treatments for muscle invasive and nonmuscle invasive bladder cancer; robotic, open, and single port cystectomy; ileal conduits and orthotopic neobladders; intravesical therapy for nonmuscle invasive bladder cancer; understanding and improving quality of life for patients with bladder cancer; blue light cystoscopy.
In addition to his clinical activities, Idr. Tyson is active in research and education, providing mentorship to trainees. He is currently recruiting patients for multiple clinical trials for patients with bladder cancer.
Learn more by visiting Dr. Mark Tyson's practice:
Podcasts Featuring Dr. Mark Tyson
.png){kind=small}
Urology Episode #267
New FDA-approved therapies for BCG-refractory non-muscle invasive bladder cancer (NMIBC)–where do they fit in the treatment algorithm, and how do you administer them? This installment of the 2025 NMIBC Creator Weekend™ series features host Dr. Bogdana Schmidt, assistant professor of Urologic Oncology at the University of Utah, and leading urologic oncologists Dr. Mark Tyson from Mayo Clinic Arizona and Dr. Suzanne Merrill from Colorado Urology.
.png){kind=small}
Tumor Board Episode #31
One of the most common dilemmas in urologic oncology: what do you do when a patient has T1 disease in both the bladder and the ureter? In the final episode of the 2025 NMIBC Creator Weekend™ series, Dr. Vignesh Packiam, Dr. Mark Tyson and Dr. Sarah Psutka share how they approach complex bladder cancer cases with upper tract involvement.
Tumor Board Episode #30
When standard therapy fails, it does not have to be the end of the road for high-risk bladder cancer patients. Modern treatments, biomarkers, and clinical studies have opened up new avenues for treating recurrent non-muscle invasive bladder cancer (NMIBC). The penultimate episode of the 2025 NMIBC Creator Weekend™ series features urologic oncologists Dr. Vignesh Packiam, Dr. Mark Tyson, and Dr. Sarah Psutka discussing how they navigate complex bladder cancer scenarios.
Tumor Board Episode #26
New FDA-approved therapies for BCG-refractory non-muscle invasive bladder cancer (NMIBC)–where do they fit in the treatment algorithm, and how do you administer them? This installment of the 2025 NMIBC Creator Weekend™ series features host Dr. Bogdana Schmidt, assistant professor of Urologic Oncology at the University of Utah, and leading urologic oncologists Dr. Mark Tyson from Mayo Clinic Arizona and Dr. Suzanne Merrill from Colorado Urology.
Get in touch!
We want to hear from you. Let us know if you’re interested in partnering with BackTable as a Podcast guest, a sponsor, or as a member of the BackTable Team.
Disclaimer: The Materials available on BackTable.com are for informational and educational purposes only and are not a substitute for the professional judgment of a healthcare professional in diagnosing and treating patients. The opinions expressed by participants of the BackTable Podcast belong solely to the participants, and do not necessarily reflect the views of BackTable.
Podcasts
Topics
More Contributors
Dr. Piyush Agarwal
Dr. Aditya Bagrodia
Dr. Kelly Bree
Meredith Donahue NP
Dr. Patrick Hensley
Dr. Lindsey Herrel